Acumen Pharmaceuticals (ABOS) Change in Account Payables (2020 - 2026)

Acumen Pharmaceuticals has reported Change in Account Payables for 7 years, with the latest figure at $1.0 million in Q1 2026.

• Quarterly Change in Account Payables rose 122.8% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $545000.0 (up 126.94% YoY) and the FY2025 annual result came in at -$5.1 million, down 219.33% from the prior year.
• Change in Account Payables improved to $1.0 million in Q1 2026 per ABOS's latest filing, from -$128000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $3.3 million in Q4 2024 and troughed at -$4.6 million in Q1 2025.
• A 5-year average of $30176.5 and a median of $121000.0 in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables sank 825.62% in 2023, then soared 19347.06% in 2024.
• Over 5 years, Change in Account Payables stood at -$444000.0 in 2022, then jumped by 103.83% to $17000.0 in 2023, then jumped by 19347.06% to $3.3 million in 2024, then slumped by 103.87% to -$128000.0 in 2025, then jumped by 917.97% to $1.0 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $1.0 million, -$128000.0, and -$1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.